Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
5.30
+0.68 (14.72%)
At close: Jun 27, 2025, 4:00 PM
5.83
+0.53 (10.00%)
After-hours: Jun 27, 2025, 7:17 PM EDT
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-$826,308
Market Cap
153.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EPRX News
- 25 days ago - Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - PRNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Announces CFO Succession - PRNewsWire
- 7 months ago - Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months - PRNewsWire